The effect of rosiglitazone on expressions of IL-18, MCP-1 and MMP-9 in rabbits with atherosclerosis
- Author:
Wen-Fen GUO
1
Author Information
1. First Clinical Medical College of Lanzhou University
- Publication Type:Journal Article
- Keywords:
Atherosclerosis;
Interleukin-18;
Matrix metalloproteinase-9;
Monocyte chemoattractant-1;
Rosiglitazone
- From:
Chinese Pharmaceutical Journal
2012;47(20):1621-1625
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To compare the effects of rosiglitazone and simvastatin on inflammatory factors in atherosclerotic rabbits and to explore the anti-atherosclerosis mechanism. METHODS: Thirty-six male New Zealand rabbits were randomly divided into four groups: control group, model group, simvastatin group, and rosiglitazone group. Subcutaneous injection of dl-homocyesteine thiolac-tone combined with high fat diet was used to reproduce atherosclerotic rabbit model, the serum level of interleukin-18 (IL-18) was examined by ELISA, and the expressions of monocyte chemoattractant-1 (MCP-1) and matrix metalloproteinase-9 (MMP-9) in aortic atherosclerotic plaque were examined by immunohistochemistry. RESULTS: Compared with the control group, the serum levels of IL-18 and the expressions of MMP-9 and MCP-1 in aortic atherosclerotic plaque were increased obviously in the other three groups (P<0.05); compared with model group, the serum levels of IL-18 and the expressions of MMP-9 and MCP-1 in rosiglitazone and simvastatin group were decreased significantly (P<0.01), the level of IL-18 in rosiglitazone group decreased significantly (P<0.05), but the expressions of MMP-9 and MCP-1 in rosiglitazone group and simvastatin group had no statistic difference (P>0.05). CONCLUSION: Rosiglitazone can decrease the serum level of IL-18 and the expressions of MCP-1 and MMP-9 in aortic atherosclerotic plaque, and inhibit the development of atherosclerosis. The mechanism is related to anti-inflammation.
